Unlike Plasmodium falciparum, Plasmodium vivax rarely causes severe disease in healthy travellers or in temperate endemic regions and has been regarded as readily treatable with chloroquine. However, in tropical areas, recent reports have highlighted severe and fatal disease associated with P. vivax infection. We review the evidence for severe disease and the spread of drug-resistant P. vivax and speculate how these maybe related.
Introduction
Plasmodium vivax threatens almost 40% of the world's population, causing an estimated 72-390 million clinical infections each year [1, 2] . Outside of Africa, Plasmodium falciparum and P. vivax almost invariably coexist and are often equally prevalent [3] , yet the public health importance of P. vivax is frequently overlooked [4] . Recent calls for the global elimination of malaria have brought renewed vigour to malaria control programmes, but with this a realization that the challenges in controlling and eliminating P. vivax are far greater than those for P. falciparum. In areas where intensive control measures have been implemented, the relative proportion of malaria due to P. vivax usually increases when compared with P. falciparum [5] . Several important biological differences account for these observations, in particular, the development of dormant liver stages (hypnozoites) causing recurrent blood stage infections (relapses), the early appearance of gametocytes and the greater transmission potential of P. vivax at low parasite densities. In the past two decades, the situation has been compounded by the emergence and spread of drug-resistant strains of P. vivax in Asia, South America and, more recently, in Africa [6-8,9 ,10 , [11] [12] [13] . The global prevalence and consequences of drug-resistant P. vivax remain poorly documented, reflecting both the inherent difficulties associated with the in-vivo test for relapsing malarias and the belief, often unsubstantiated, that chloroquine continues to be effective.
Although usually considered a benign infection, there is a growing appreciation that vivax malaria causes significant morbidity and inflicts a huge socio-economic burden on endemic countries [1]. Reports of severe and fatal malaria from the island of New Guinea and from India have reinforced this [14 -17 ] and demand a reappraisal of the pathogenesis of this infection. In this article, we review the evidence describing severe manifestations of vivax malaria and the literature on the extent and degree of drug resistance in P. vivax; we speculate on how these may be related.
Epidemiology of severe vivax malaria
In coendemic regions, a significant proportion of patients admitted to hospital with malaria have P. vivax monoinfection. Recent studies from Indonesia, Papua New Guinea (PNG), Thailand and India show this figure to vary from 20 to 40% [14 ,15 ,17 ,18] . P. falciparum remains the dominant species associated with classically defined severe malaria but, depending on the setting, P. vivax can account for up to a quarter of all severe cases detected [14 -16 ] . A broad range of severe manifestations has been reported, some of which have been associated with subsequent death. In Papua, Indonesia, the overall mortality among those hospitalized with P. vivax is 0.8-1.6%, similar to that observed with pure P. falciparum (1.6-2.2%) [14 ,15 ] .
Infants are particularly vulnerable to infection with P. vivax. Indeed in southern Papua, where P. falciparum is the most prevalent species, more infants are hospitalized with vivax malaria than with falciparum malaria [19] . In this age group, P. vivax infection is associated with an increased risk of severe anaemia [odds ratio (OR) ¼ 2.4] and thrombocytopenia (OR ¼ 3.3) compared with infants with P. falciparum. The risk to infants starts with in-utero exposure, which is associated with maternal anaemia, prematurity and low birth weight, all of which are known to contribute to overall infant mortality [20, 21] .
Severe manifestations
Almost all of the severe manifestations of falciparum malaria have also been described in vivax malaria [4, 22 ] . Severe anaemia (haemoglobin level < 5 g/dl) is the most common in Papua (67-80% of cases) [14 ,15 ] ] and accounted for a third of severe cases in an Indian series [17 ] . A study from Venezuela also found anaemia to be more severe and frequent in P. vivax infections compared with P. falciparum [23] . Although the associated mortality in Papuan patients with severe anaemia alone was low (0.4%), it rose considerably when other manifestations of severity were present (10-39%) [15 ] . Recurrent bouts of P. vivax infection, whether from reinfection, relapse or recrudescence, result in the removal of both uninfected and infected red cells from the peripheral circulation. Haemolysis, increased red cell fragility [24] , dyserythropoiesis and retention of erythrocytes within the spleen [25 ,26] , all contribute to severe anaemia, though their relative contributions are poorly defined. P. vivax frequently affects the lung with cough occurring in the majority of patients [27] . Respiratory distress was the primary manifestation of severity in PNG where it was reported in 5% of children infected with P. vivax [16 ] , but is described less frequently elsewhere. In adults, acute lung injury has been described as the cause of acute respiratory distress in returning travellers with vivax malaria, most of whom had a diagnosis of P. falciparum coinfection excluded by PCR [27, 28] . Inflammatory increases in alveolar-capillary membrane permeability [27] [28] [29] as well as mononuclear cell accumulation in the pulmonary microvasculature are likely to underlie this syndrome [22 ] . In endemic areas, the majority of vivaxassociated respiratory distress occurs in children, an age group in which acute lung injury is rare [15 ,16 ] . This suggests that though acute lung injury appears to be a major cause of vivax-associated respiratory distress in adults, other causes such as anaemia, acidosis and concurrent respiratory tract infections are likely to contribute to vivax-associated respiratory distress in children.
Jaundice and renal failure have been reported in series of adults from India [17 ] and northern Papua [14 ] . Coma occurs in association with P. vivax but is rare compared with its frequency in severe falciparum malaria [30, 31] . Severe thrombocytopenia and acidosis have also been reported [28] .
Although P. vivax-P. falciparum coinfection has previously been associated with a reduced risk of severe malaria, the recent studies from across New Guinea have shown an increased risk of severe malaria in mixed infections, particularly severe anaemia [14 ,15 ] .
Association or causation?
Reports of severe vivax malaria challenge our understanding of P. vivax pathophysiology [22 ] . Processes central to the development of severe disease in falciparum malaria, including high parasite biomass, widespread sequestration of cytoadherent parasites and reduced deformability of infected and uninfected red cells, are not found in vivax malaria (though a role for limited or transient cytoadherence has been proposed [22 ,26-28] ). However, there are a number of caveats in interpreting these reports of severe vivax malaria. As with severe falciparum malaria, incidental parasitaemia, sepsis and comorbidities are likely to be important contributory factors [32] . Furthermore, only one of the large descriptive studies was able to rule out microscopy errors and occult mixed plasmodium infections [17 ] .
The geographical variation in the risk of severe vivax malaria is striking. In temperate regions where relapses are infrequent [33] and in areas where early diagnosis and radical cure are readily available, the risk of severe disease from single infections is low and largely confined to acute lung injury [27, 28] . In contrast, severe and fatal vivax malaria is more frequent in poorly resourced endemic regions where populations have limited access to healthcare and suffer from a complex array of comorbidities, nutritional, genetic and immunological disorders, all of which may contribute to the pathology. In many of these areas, P. vivax can be a chronic relapsing disease, similar to that described in temperate climates in the preantibiotic era when vivax malaria was known to cause a debilitating febrile illness that could last for years with appreciable morbidity.
Heterogeneity in parasite virulence may also play a role in the clinical spectrum of disease. Indeed, differences in the virulence of P. vivax strains were well described in the malaria therapy era, with some strains reportedly leading to recovery without treatment, whereas others were associated with case-fatality rates of 10-14% [34] . Recent laboratory studies raise the possibility that such virulence may be associated with chloroquine-resistant (CQR) P. vivax which, compared with chloroquine-sensitive isolates, have faster parasite growth rates [35 ] , a phenotype correlated with severe falciparum malaria [36] . The risk of severe falciparum malaria and malaria mortality has been previously associated with the rise of chloroquine resistance in P. falciparum [37] ; a similar pattern may now be occurring in parallel with the rise in CQR P. vivax.
The importance of recurrent parasitaemia
The radical cure of vivax malaria demands effective treatment of both the asexual stages of the parasite as well as the dormant hypnozoite stages. For the past 60 years, the only available treatment of P. vivax hypnozoites has been primaquine which has traditionally required a 14-day regimen that is associated with both poor adherence and effectiveness. The emergence of CQR P. vivax has exacerbated the problem. Studies in Papua, Indonesia reveal that 2% of patients receiving chloroquine monotherapy subsequently require admission to hospital [8], with 60-90% of patients having recurrent malaria within 28 days [8, 9 ,38] . Such poor therapeutic efficacy is highly likely to contribute to the cause of severe disease, particularly that of severe anaemia. In addition, the haemodynamic and respiratory consequences of fever or anaemia or of both combined with other acute infections (for example pneumonia) or chronic diseases, common in endemic areas, may lead to decompensation with potentially fatal outcome from a P. vivax infection that might otherwise be uncomplicated [22 ] .
Drug-resistant Plasmodium vivax
The first cases of CQR P. vivax were documented in 1989 [39] , 30 years after reports of the emergence of CQR P. falciparum. This difference in the speed with which resistance develops is likely to reflect a number of intrinsic differences between the two species. Selective drug pres-sure, a crucial determinant of de-novo selection [40] , is significantly lower in P. vivax infections, a consequence of asymptomatic parasitaemia and lower parasite biomass. In P. falciparum infections, gametocytogenesis occurs after the appearance of symptoms and is refractory to schizontocidal drugs, thus favouring the transmission of resistant genotypes. In contrast, P. vivax gametocytes appear early and are susceptible to schizontocidal agents, ensuring transmission occurs prior to drug selection.
Diagnosis of drug resistance
In the absence of empirical evidence to the contrary, it is often assumed that established chloroquine treatment protocols continue to be effective. Between 1966 and 2002, only 11% (47 out of 435) of published antimalarial drug trials assessed antimalarial efficacy in vivax malaria [41] . This reflects the challenges of conducting such studies and interpreting the clinical drug efficacy for P. vivax. Although three-loci genotyping has proved useful in defining recrudescence in P. falciparum, it has limited utility in P. vivax as recurrent infections with the same genotype can arise following both recrudescence and relapse, the latter occurring early in up to 80% of patients after treatment [9 ] . Clinical efficacy, therefore, has to be interpreted in light of the timing of recurrences, plasma drug concentrations, the half life of the drug and the early parasitological response [6].
In-vitro drug susceptibility assays provide an alternative means of assessing drug susceptibility of Plasmodium spp. free from the confounders of host immunity, relapse and reinfection. However, the preferential invasion by P. vivax of young red blood cells limits its reproductive capacity and the ability to culture the parasite ex vivo [42] . Success has been achieved in evaluating the inhibitory effect of antimalarials on fresh asexual stages of the parasite from the human host after short-term cultivation [43] [44] [45] [46] . However, isolates of P. vivax initially at the trophozoite stage are intrinsically resistant to chloroquine [35 ,47] . As P. vivax infections are typically asynchronous and the degree of asynchronicity varies between geographical locations, the in-vitro drug response needs to interpreted according to the initial stage of the parasite and the duration of the assay [35 ] . Despite these difficulties, the current in-vitro susceptibility assay has shown utility in confirming the presence of emerging drug resistance [46, [48] [49] [50] , characterizing drug susceptibility profiles [50, 51] and the screening of susceptibility to therapeutic agents [52] .
Geographical extent of chloroquine resistance
The discovery of CQR P. vivax in PNG [39] was soon followed by reports from northern Papua, Indonesia [7, 53] . Over the ensuing decades, high-grade CQR emerged in eastern Indonesia [8, 38, 54] and PNG [9 ] . The western provinces of Indonesia have also reported reduced susceptibility, albeit to a lesser degree [55] [56] [57] . Low-level chloroquine resistance is present in Burma [12] , Viet Nam [58, 59] , South Korea [60] , Turkey [61] , the horn of Africa [13] , Madagascar [62] , South America [10 ,63] and eastern India [64] . Although studies from Thailand have mostly recorded excellent cure rates [43, 65] , a recent large study on the western border found 10% recurrence at day 28 (F. Nosten, personal communication). Chloroquine appears to retain high efficacy against P. vivax in most of India [66] , Afghanistan [67] , Pakistan [68] and Azerbaijan [69] , though ongoing surveillance is warranted.
Genetic basis of Plasmodium vivax drug resistance
Preliminary studies on drug resistance in P. vivax have focused on the orthologues of the transporter genes pfcrt and pfmdr1, known to be key determinants in P. falciparum resistance. Although chloroquine resistance does not appear to be associated with polymorphisms in pvcrt [48, 62, 70] , studies from Indonesia, Thailand and PNG found that a Y976F pvmdr1 polymorphism correlated with reduced susceptibility to chloroquine both in vitro [48] and in vivo [71] . However, as chloroquine resistance can occur in isolates with wild-type pvmdr1 [48, 72] and cure can be achieved in the presence of the 976 mutation [62] , pvmdr1 mutations are likely to be at best only minor determinants of resistance.
In contrast to chloroquine resistance, amplification of the pvmdr1 gene is associated with a two-fold reduction in in-vitro susceptibility to mefloquine [51] . Imwong et al. found amplification of pvmdr1 in P. vivax isolates and correlated this with the clinical use of mefloquine in Thailand and Myanmar [73 ] . Hence, even though chloroquine remains the standard treatment for P. vivax in this region, the use of mefloquine for P. falciparum and mixed infections is enough to exert selective pressure on pvmdr1. Sequential acquisition of mutations in pvdhfr and pvdhps is also observed where P. vivax is exposed to intense antifolate pressure [71, [74] [75] [76] .
Treatment options for chloroquine-resistant Plasmodium vivax
Mefloquine and atovaquone-proguanil retain excellent efficacy against highly CQR P. vivax [77] [78] [79] , whereas amodiaquine monotherapy appears to be compromised [49] . Of the artemisinin combination therapies (ACTs), dihydroartemisinin-piperaquine produces the lowest failure rates at day 28 [9 ,80,81,82 ] . In contrast, artesunatesulfadoxine/pyrimethamine is associated with recurrence rates in excess of 10% at day 28 [9 ,76] , and this rises to over 20% for artemether-lumefantrine [9 ,82 ] . As none of these antimalarial drugs has any efficacy on the hypnozoite stages of P. vivax, the difference in recurrence rates is likely to be a consequence of the different terminal elimination half-lives of lumefantrine (4 days), amodiaquine (18 days) and piperaquine (28-35 days) exerting different posttreatment prophylactic effects on relapsing infection. Further studies to rationalize regimens containing asexual and hypnozoite activity are needed [83] .
Conclusion
P. vivax produces an acute febrile illness with the potential to become chronic and relapsing if inadequately treated. In comparison with the more pathogenic P. falciparum, P. vivax rarely causes severe disease in healthy individuals from nonendemic countries or temperate regions. In contrast, recent reports from tropical endemic communities highlight a high risk of severe disease and an association with mortality. In some regions, the risk of severe disease caused by vivax malaria in patients reaching hospital approaches that of falciparum malaria. However, reports of vivax-associated severe disease need to be interpreted with caution as they are likely to be confounded by microscopy errors, coinfection with P. falciparum and comorbidities such as bacterial sepsis and malnutrition. The crucial question remains: how much of the severe disease and mortality is associated with vivax infection and how much is actually attributable to P. vivax? Confirmation of the latter demands a reappraisal of our understanding of the pathobiology of the parasite and exclusion of comorbidities. Even if P. vivax is a secondary or contributory factor in the cause of severe disease, this still has important public health implications for poorly resourced endemic regions. Evidence is mounting that delay in diagnosis of P. vivax, the application of partially effective treatment regimens and our inability to reliably cure the dormant stages of the parasite all cause significant host morbidity and contribute to the socio-economic burden of this neglected parasite. In this context, the emergence and spread of high-grade drug-resistant P. vivax poses a major threat to endemic countries that must be quantified and contained if there is to be any realistic prospect of the global elimination of malaria.
